[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 1 of 43 A PILOT STUDY OF [18F]F-ARAG PHARMACOKINETICS IN TUMORS AND NON-
MALIGNANT  TISSUE USING DYNAMIC TOTAL BODY PET IMAGING IN 
HEALTHY SUBJECTS AND IN PATIENTS WITH NON- SMALL CELL LUNG 
CANCER (NSCLC)  
Study Number:  CST-FARAG -203   
Indication:  Non-Small Cell Lung Cancer (NSCLC)  
Phase:  Pilot  
Funding Source(s):  Cellsight  
Agent / Modality:  [18F]F-ARAG/TOTAL BODY PET IMAGING  
Coordinating Center:  Department of Radiology  
EXPLORER Molecular Imaging Center  
3195 Folsom Blvd, Suite 120 
Sacramento, CA 95816  
Phone: 916- 731-9000 
Fax: 916- 451-0119  
 
Principal Investigator:  Simon R. Cherry, Ph.D.  
Professor  
Department of Biomedical Engineering and  
Department of Radiology  
University of California, Davis  
3195 Folsom Blvd, Suite 120, Sacramento, CA 95817 Telephone: (916) 731 -9010 
Email: srcherry@ucdavis.edu  
Co-Principal 
Investigator:  Megan Daly, MD  
Department of Radiation Oncology  University of California Davis Comprehensive Cancer Center School of Medicine  
4501 X Street, G -140 Sacramento, CA 95817  
Telephone: (916) 734 -5428  
Email: medaly@ucdavis.edu  
IND Sponsor:  Cellsight  
IND # :  123591  
Version:  1.0:  06.08.2021   
1.1:  09.17.2021 1.2:  05.03.2022 1.3:  06.30.2022 
1.4:  04.23.2024  
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 2 of 43  
PROTOCOL SIGNATURE PAGE  
 
Protocol Number:  CST -FARAG-203 
Protocol Title:  A Pilot Study of [18F]F-ARAG Pharmacokinetics in Tumors and Non -Malignant 
Tissue using Dynamic Total Body PET Imaging in Healthy Subjects and in Patients with Non-
Small Cell Lung Cancer (NSCLC)  
I have read this protocol and agree that it contains all necessary details for carrying out this study. 
I will conduct the study as outlined herein and will complete the study within the time designated, 
in accordance with all stipulations of the protocol and in accordance with Good Clinical Practices, local regulatory requirements, and the Declaration of Helsinki.  
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who assist in the conduct of this study. I will discuss this material with them to ensure that they 
are fully informed regarding the study agent(s) and the conduct of the study.  
 
Simon R. Cherry, PhD_              
Investigator Name (print)                          
 
__________________________________ Investigator Signature  
 
__________________________________ Date  
 
 
 
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 3 of 43 SCHEMA  
 
 
Study Flow Diagram ( Healthy  Subjects)  
 
 
 
 
 
Study Flow Diagram (NSCLC Subjects)  
 
 
NOTES:  
1. IMMUNOTHERAPY IS NOT A PART OF THIS STUDY BUT IS A PART OF SOC TREATMENT OF THESE PATIENTS  
2. THE POST -TREATMENT [18F]F-ARAG  PET/CT SCAN IS OPTIONAL FOR PATIENTS  
Name of Sponsor/Company: CellSight Technologies  
Name of Study Product: [18F]F-AraG  
Protocol Number: CST -FARAG -203 
 Indication:  
• Healthy subjects  
• non-small cell lung cancer (NSCLC) patients   
Title of Study:  
A pilot study of [18F]F-AraG pharmacokinetics in tumors and non- malignant tissue using dynamic total body PET imaging in healthy subjects and in patients with 
non-small cell lung cancer (NSCLC).  
Study Center:  UC Davis Comprehensive Cancer Center  
Planned Number of Subjects:  
2-4 healthy subjects  
2-4 NSCLC subjects  Study Development Phase:  
Phase I/II  
Study Outcome Measures:  
• Quantitative assessment of [18F]F-AraG biodistribution  in healthy tissues as a function of time.  
• Quantitative assessment of [18F]F-AraG biodistribution in tumor lesions  relative to non-malignant tissues in NSCLC subjects as a function of time . 
• Recommended post -infusion time window to acquire a static [18F]F-AraG PET/CT scan.  
• Quantitative assessment of change in PET signal pre - and post -  first dose of PD -1/PD -L1 immunotherapy. 

[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 4 of 43 TABLE OF CONTENTS  
 
PROTOCOL SIGNATURE PAGE  ..............................................................................................2 
SCHEMA  ........................................................................................................................................3 
TABLE OF CONTENTS  ..............................................................................................................4 
LIST OF TABLES  .........................................................................................................................7 
LIST OF FIGURES  .......................................................................................................................7 
LIST OF ABBREVIATIONS  .......................................................................................................8 
1. BACKGROUND ..............................................................................................................10 
1.1 Therapy Approaches for NSCLC  ...........................................................................10 
1.2 Immune -Checkpoint Blockade Immunotherapy Approaches  ................................10 
1.3 Need for Tumor Response Assessment  .................................................................10 
1.4 A Specific T -Cell Activation Imaging Agent for Tumor Response Assessment  ..10 
1.5 Investigational Agent: [18F]F-AraG  .......................................................................11 
1.5.1 Preclinical Characterization  ..................................................................11 
1.5.2 Clinical experience  ................................................................................13 
2. STUDY RATIONALE  .....................................................................................................15 
3. OBJECTIVES  ..................................................................................................................17 
3.1 Primary Objectives .................................................................................................17 
3.2 Secondary Objectives .............................................................................................17 
4. STUDY POPULATION ..................................................................................................17 
4.1 Inclusion Criteria  ...................................................................................................17 
4.2 Exclusion Criteria  ..................................................................................................18 
4.3 Subject recruitment  ................................................................................................19 
4.3.1 NSCLC Subjects:  ..................................................................................19 
4.3.2 Healthy Subjects:  ..................................................................................19 
5. STUDY DESIGN  ..............................................................................................................19 
5.1 Study Calendar  .......................................................................................................20 
5.2 Participant Duration  ...............................................................................................21 
6. MATERIALS AND METHODS  ....................................................................................22 
6.1 Study DRUG: [18F]F-AraG  ....................................................................................22 
6.1.1 Manufacture  ..........................................................................................22 
6.1.2 Availability  ............................................................................................22 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 5 of 43 6.1.3 Agent Ordering......................................................................................23 
6.1.4 Study Treatment Accountability  ...........................................................23 
6.1.5 Dispensing [18F]F-AraG  ........................................................................23 
6.2 uEXPLORER PET/CT Scan  ..................................................................................24 
7. RISKS TO SUBJECTS ....................................................................................................24 
7.1.1 Risks from [18F]F-AraG PET/CT scan  ..................................................24 
7.1.2 Radiation Risk  .......................................................................................26 
8. POTENTIAL BENEFITS TO SUBJECTS  ...................................................................27 
9. CONCOMITANT MEDICATIONS  ..............................................................................27 
10. OUTCOME MEASURES AND ANALYSIS  ................................................................27 
10.1 Physiological Time -Activity Curves of [18F]F -AraG Uptake within Healthy 
Tissues....................................................................................................................27 
10.2 Time -Activity Curves of [18F]F-AraG Uptake within Tumors and Background 
Tissues....................................................................................................................27 
10.3 Recommended time post [18F]F-AraG infusion to acquire a single static 
PET/CT scan  ..........................................................................................................28 
10.4 Change in PET signal pre - and post - first dose of PD -1/PD -L1 
immunotherapy ......................................................................................................28 
10.5 Safety Outcome Measures  .....................................................................................28 
10.6 Efficacy Outcome Analysis  ...................................................................................28 
11. STATISTICAL METHODS AND DATA ANALYSIS  ................................................29 
11.1 Number of Subjects ................................................................................................29 
11.2 Scan Data  ...............................................................................................................29 
11.3 General Statistical Considerations  .........................................................................29 
11.4 Analysis populations  ..............................................................................................29 
11.4.1 Efficacy population ...............................................................................29 
11.4.2 Per-protocol (PP) Population ................................................................29 
11.4.3 Safety Population ..................................................................................29 
11.5 Statistical Methods  .................................................................................................29  
11.5.1 Subject Disposition  ...............................................................................29 
11.5.2 Demographics and baseline characteristics analysis  .............................30 
11.5.3 Concomitant Medications/Therapies  ....................................................30 
11.5.4 Medical history ......................................................................................30 
11.5.5 Study Treatment Compliance  ................................................................30 
 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 6 of 43 12. SAFETY REPORTING OF ADVERSE EVENTS  .......................................................30 
12.1 Assessment of Safety  .............................................................................................30 
12.2 Adverse Events  ......................................................................................................30 
12.3 Reporting of Adverse Events  .................................................................................31 
12.4 Methods and Timing for Assessing and Recording Safety Variables  ...................31 
12.5 Assessment of Adverse Events  ..............................................................................31 
12.6 Causality  ................................................................................................................32 
12.7 Reporting Requirements for SAEs  .........................................................................33 
13. QUALITY CONTROL AND QUALITY ASSURANCE  .............................................33 
13.1 Monitoring Requirements  ......................................................................................33 
13.2 Acceptability of Case Report Forms  ......................................................................34 
13.3 Modification of Protocol  ........................................................................................34 
13.4 Reporting Protocol Deviations  ...............................................................................34 
13.5 Subject Premature Withdrawal from Study  ...........................................................34 
14. DATA AND SAFETY MONITORING COMMITTEE  ..............................................35 
15. ETHICAL CONSIDERATIONS AND ADMINISTRATIVE PROCEDURES  ........36 
15.1 Ethics and Good Clinical Practice  .........................................................................36 
15.2 IND Holder Information  ........................................................................................37 
15.3 Institutional Review Board/Independent Ethics Committee ..................................37 
15.4 Informed Consent ...................................................................................................37 
15.5 Sharing of Results with Subjects  ...........................................................................38 
15.6 Disclosure and Confidentiality ..............................................................................38 
15.7 Declaration of Helsinki  ..........................................................................................39 
15.8 Compensation for Research -Related Injury  ...........................................................39 
15.9 Economic Burden to Subjects  ................................................................................39 
16. REFERENCES  .................................................................................................................40 
17. APPENDICES  ..................................................................................................................42 
Appendix 1: ECOG and Karnofsky Performance Status Scores1,2  ...................................42 
Appendix 2: Study Registration and Participant visits  ......................................................43 
 
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 7 of 43 LIST OF TABLES  
Table 1: Study Schedule of Events (Healthy Volunteers)  .............................................................20  
Table 2: Study Schedule of Events (NSCLC subjects)  ..................................................................21  
Table 3: CTCAE v5.0 General Guidelines  ....................................................................................32  
 
LIST OF FIGURES  
Figure 1:  [18F]F AraG accumulation in activated T cells.  ............................................................12  
Figure 2: Visualization of endogenously induced anti -tumor immune response  ..........................13  
Figure 3: Whole body [18F]F AraG PET image in a healthy volunteer.  ........................................14  
Figure 4: [18F]F-AraG PET/CT images pre and post Anti PD 1 Ab therapy. ................................15  
 
 
 
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 8 of 43 LIST OF ABBREVIATIONS  
%  Percent  
AE  Adverse Event  
ANCOVA  Analysis of Covariance  
BMI   Body Mass Index  
BUN   Blood Urea Nitrogen  
CBC  Complete Blood Count  
CFR  Code of Federal Regulations  
CRF   Case Report Form  
CFR  Code of Federal Regulations  
CRO   Contract Research Organization  
CT  Computed Tomography  
CTL   Cytotoxic T -Lymphocytes  
CTCAE  Common Terminology criteria for Adverse events  
CV  Curriculum vitae  
DLT   Dose Limiting Toxicity  
DP  Drug Product  
DSMC   Data Safety and Monitoring Committee  
ECG   Electrocardiogram  
ECOG   Eastern Cooperative Oncology Group  
FDA  Food and Drug Administration  
FDG  Fluorine -18-flurodeoxyglucose  
g/dL   grams/deciliter  
GCP   Good Clinical Practices  
GLP   Good Laboratory Practice  
GMP   Good Manufacturing Practices  
HPB   Human Peripheral Blood  
HIPAA   Health Insurance Portability and Accountability Act  
HR  Heart Rate  
IA  Interim Analysis  
ICF  Informed Consent Form  
ICH  International Conference on Harmonization  
IHC  Immunohistochemistry  
IND  Investigational New Drug  
IEC  Independent Ethics Committee  
IP  Investigational Product  
IRB  Institutional Review Board  
ITT  Intent -to-Treat  
IUD  Intra Uterine Device  
IV  Intravenous  
Kg  Kilograms  
Mg  Milligram 
mCi  MilliCurie  
MRI   Magnetic resonance imaging  
MedDRA  Medical Dictionary for Regulatory Activities  
mg/dL   Milligram/deciliter  
mmol/L   Millimole/Liter  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 9 of 43 msec  Milliseconds  
NSCLC   Non-Small Cell Lung Cancer  
PBMC  Peripheral Blood Monocyte Cells  
PD1  Programmed cell death protein  
PDL1   Programmed cell death protein ligand  
PET  Positron emission tomography 
PI  Principal Investigator  
PK  Pharmacokinetics  
PP  Per Protocol  
RBC  Red Blood Cells  
RECIST  Response evaluation criteria in solid tumors  
RR  Respiration Rate  
SAE   Serious Adverse Event  
SAP  Statistical Analysis Plan  
SD  Standard Deviation  
SOC   Standard of Care  
SOP  Standard Operating Procedures  
SUV  Standardized uptake value  
TBD   To be determined  
TEAE  Treatment Emergent Adverse Event  
TV  Treatment Visit  
Tx  Treatment, Cancer Treatment  
U/L  Units/Liter  
USA  United States of America  
USP  United States Pharmacopeia 
WBC  White Blood Cells  
WBS   Whole Body Scan  
WHO  World Health Organization  
μL  Microliter    
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 10 of 43 
 BACKGROUND 
 Therapy Approaches for NSCLC  
Lung cancer is the leading cause of cancer -related deaths in both men and women in the US. 
(https://seer.cancer.gov/statfacts/html/lungb.html). The majority of NSCLC patients present with 
advanced  or metastatic disease, which is not amenable to surgical resection.  
Immunotherapy has attracted much attention in recent years, since (i) identification of molecularly-defined tumor antigens (TA) [ 1, 20] has provided well defined moieties to be used as immunogens 
and as markers to monitor the immune response; (ii) characterization of the molecular steps leading to an immune response [ 5, 6] has facilitated the development of effective immunization strategies; 
and (iii) availability of cytokines has provided reagents to modulate the immune response. Because of the general belief that T cells play a major role in the control of tumor growth [ 15, 16], the 
application of T cell -based immunotherapy has been emphasized.  
 Immune -Checkpoint Blockade Immunotherapy Approaches  
Immunotherapies have changed the treatment strategy of some types of  tumor  including melanoma 
and, more recently, non- small- cell lung cancer (NSCLC). Immune checkpoints are crucial for the 
maintenance of self -tolerance and it is known that some tumors use checkpoint systems to evade 
antitumor immune response. The treatment of advanced  NSCLC by immunotherapy, such as 
immune -checkpoint blockade targeting the programmed cell  death protein- 1 (PD1/PDL1) , has led 
to significant clinical benefit either as monotherapy or in combination  therapy [ 4]. 
 Need f or Tumor Response Assessment  
The landscape of novel cancer therapies is undergoing fundamental changes, with great promise in the immunotherapy trials as illustrated by the United States Food and Drug Administration (FDA) approval of multiple checkpoint inhibitors for various cancer i ndications, a monoclonal 
antibody (mAb), ipilimumab, for treatment of metastatic melanoma [ 12] and a vaccine for prostate 
cancers as the first vaccine against non -viral cancers [ 13]. There is a pressing need for accurate, 
timely assessment of immunotherapy treatment response in cancer patients to improve clinical management and facilitate drug development. A standard for response assessment is measuring 
tumor size with CT or MR and t hen classifying tumor size reduction according to RECIST [ 8]. 
RECIST and other standard response measures are ill suited to monitor response to 
immunotherapy, largely due to “pseudoprogression” caused by immune mediated increase in 
contrast enhancement. However, molecular imaging can measure important biologic responses 
that precede tumor size reduction , such as cellular metabolism, proliferation, and vascularity. 
 A Specific T -Cell Activation Imaging Agent for Tumor Response Assessment  
Early preclinical and clinical studies have shown promise for immunotherapy treatments for 
several malignancies [ 22]. Immunotherapy is expected to grow in importance; however, it presents 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 11 of 43 difficult challenges for response assessment. For instance, successfully treated tumors may 
actually increase in size after therapy due to inflammation and only later shrink [ 25]. RECIST 
criteria [8] designed to detect early effects of cytotoxic agents by size reduction, or the more 
recently proposed immune -related response criteria (irRC) [ 19] do not allow an early assessment 
of immunotherapeutic response since both depend on tumor size change. Furthermore, FDG PET is confounded by inflammatory effects causing hypermetabolism [ 2, 11] . Thus, it is imperative to 
develop new imaging and analysis protocols to evaluate immune -checkpoint blockade approaches.  
A method that evaluates T cell activation would permit an assessment of a basic first step in the process of assessing immunotherapy efficacy.  
 Investigational Agent: [18F]F-AraG  
CellSight Technologies  (CST), Inc. is a company that is developing a suite of PET tracers targeted 
at visualizing immune response early in a patient's immunotherapy regimen.  Their lead PET imaging tracer targeted at imaging activated T -cells is a fluorine -18-labeled analog of an 
FDA -approved drug Nelarabine [
18F]F-AraG, trade name VisAcT.  VisAcT is independent of the 
type of immunotherapy regimen being administered -  adoptive cell therapy, checkpoint inhibitors, 
cancer vaccines or a combination of immunotherapy and conventional medicines.  VisAcT is relatively specific to activated T -cells that are critical to any immune modulated therapy.  In vivo, 
real time imaging of activated T -cells in solid tumors before and at a timepoint during and after  
checkpoint inhibitor therapy (CkIT therapy)  can help understand the effects of check point 
blockade therapy.  Additionally, in vivo whole -body imaging of activated T -cells can provide 
critical information about the effect of immunomodulation in autoimmune diseases, as well as help their prediction as adverse events.   
1.5.1 Preclinical Characterization  
Molecular imaging of immune activation by positron emission tomography (PET) is a potential noninvasive strategy to monitor immune activation after treatment with immunotherapy.  Increased activity of nucleoside salvage pathways has been associated with th e proliferation of 
adaptive and innate immune cells [ 10, 24].  In preclinical models of cancer and autoimmunity, the 
PET probe [
18F]–2-fluoro -d-(arabino -furanosyl)cytosine ([18F]-FAC), which targets the 
deoxycytidine salvage pathway, was shown to localize to sites of immune activation [ 21] and is 
predominantly accumulated in proliferative CD8+ T -cells [ 17]. 
Recently, a radiofluorinated AraG imaging agent,  [18F]F-AraG(2′ -deoxy- 2′-fluoro- 9-β-D-arabino -
furanosylguanine;   trade name VisAcT) was synthesized [ 18] with a goal of development for 
human use.  F -AraG is a fluorinated purine derivative with selective T -cell toxicity.  A 
water -soluble AraG prodrug, Nelarabine, is FDA approved for the treatment of relapsed T -cell 
acute lymphoblastic leukemia and T -cell lymphoblastic lymphomas [ 7]. [18F]F-AraG 
preferentially accumulates in murine and human activated T -cells than in naive T -cells ( Figure 1).  
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 12 of 43 [18F]F-AraG  was evaluated in three different preclinical models: rheumatoid arthritis  [9], GvHD 
[23], colon cancer [14]. 
Figure 1:  [18F]F AraG accumulation in activated T cells.  
  
Figure  1:  [18F]F-AraG preferentially accumulates in activated T -cells than in naive T -cells.  A ) Uptake of 
[18F]F-AraG in human and mouse primary T -cells post -stimulation.  B ) Pan T -cells were isolated from spleen and 
lymph nodes of mice.  Untreated cells as well as CD3/CD28 activated T -cells (48 hours) were incubated with 
[18F]F-AraG before subcutaneous implantation into the shoulders before PET/CT imaging.  
The accumulation of [18F]F-AraG in human activated T -cells is also significantly higher than other 
immune cells, including B cells, macrophages, and dendritic cells [14] .  Furthermore, 
endogenously induced anti -tumor immune response in a viral induced rhabdomyosarcoma (MSV) 
mouse model was correlated with enhanced [18F]F-AraG uptake within the tumors ( Figure 2A ).  
Analysis of isolated tumors showed that tracer preferentially accumulated in activated CD8+ 
T-cells ( Figure 2B ). 
 
 

[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 13 of 43 Figure 2: Visualization of endogenously induced anti -tumor immune response  
Figure  2:  Visualization of endogenously induced anti -tumor immune response in a viral induced rhabdomyosarcoma 
(MSV) mouse model with [18F]F-AraG PET.  A) Viral induced rhabdomyosarcoma was implanted in the left hindleg, 
and P815 mastocytoma (control) was implanted in the right shoulder.  PET/CT was performed on Day 14 during the 
peak anti -tumor immune response in the rhabdomyosarcoma model.  B ) CD8+, CD4+ and C19+ cells were isolated 
from rhabdomyosarcoma tumor one hour after probe injection for radioactivity assay.  Lymphocytes take up more than 
80% of tumor associated [18F]F-AraG, with CD8+ and CD4+ cells acquiring the largest portion of the tracer (72%). 
The low uptake in B cells (CD19) is only observed in mice. Human B cells do not accumulate the tracer.  C) FACS 
analyses of the isolated lymphocytes showed an activated phenotype (CD44+ CD62L -) in majority of CD8+ 
(79.9±11.5) and CD4+ cells (88.3±11.7). Error bars represent standard deviation.  
1.5.2 Clinical experience  
The first -in-human study of [18F]F-AraG was performed at UCSF in 2015 ( abstract of meeting 
presentation available here:    
http://www.wmis.org/meetings/archives -of-past-meetings/wmic -2015- first-in-human- study- 3/).  
[18F]F-AraG was administered at a subpharmacologic, tracer microdose consistent with imaging 
practices in six healthy volunteers (3 males and 3 females).  The distribution of the tracer was 
evaluated over the first 4 hours after injection.  A representative whole  body PET/MR image in a 
healthy volunteer is shown in Figure 3 ([23]; [18F]F-AraG Investigator’s Brochure) .  The tracer 
was well tolerated by all patients and there were no > Grade 1 adverse events  (AE).  The only AE 
that occurred in more than 1 volunteer was positive white blood cell  (WBC ) esterase in the 
urinalysis without urinary symptoms.  Normal uptake was seen in the clearance organs: liver, 
kidneys and bladder.  There appeared to be uptake in the thyroid and parotid glands, as well as 

[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 14 of 43 limited accumulation in the cardiac muscle.  In these first- in human studies, no additional drugs 
were administered to subjects as the biodistribution was determined for radiation dose estimates.   
[23].  
Figure 3: Whole body [18F]F AraG PET image in a healthy volunteer.  
 
  
Figure  3:  Maximum intensity projection (MIP) of a whole body [18F]F-AraG PET image of a healthy volunteer 
acquired 90 minutes post infusion.  
 [18F]F-AraG is currently being tested in several  Phase I /II clinical trials.  The clinical trials aim to 
evaluate the use of [18F]F-AraG in cancer patients undergoing immunotherapy. Cancer types 
include solid tumors of all types including, among others, lung cancer, melanoma, breast cancer 
and head & neck cancer.  Non-oncology focused trials include an HIV trial at UCSF to help see 
differences in repositories of T cells in HIV patients and a trial at Stanford is determining if [
18F]F-AraG will be useful as an early predictor of Graft vs Host Disease .  
Investigators from Stanford have reported early clinical evidence that [18F]F-AraG PET scans 
demonstrate imaging of activated T -cells in vivo.  In a study that aims to evaluate immunological 
response to Anti -PD-1 treatment in squamous cell carcinoma of the head and neck (SCCHN), 

[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 15 of 43 investigators reported a correlation in the change in total SUV and change in the CD8+T -cells post 
PD-1 antibody infusion ( Figure 4).  
Figure 4: [18F]F-AraG PET/CT images pre and post Anti PD 1 Ab therapy.  
 
Figure  4:  [18F]F-AraG PET/CT images of 2 SCCHN  patients pre and post Anti -PD-1 Ab therapy.  [18F]F-AraG signal 
increased dramatically after only one injection of PD -1 Ab in Patient A.  FACS analysis revealed a higher  proportion 
of both CD8+ cells and higher expression of CD38 activation marker after one treatment.  In Patient B,  there was not 
a significant increase in total SUV in VOI and correspondingly there was not an increase in the  CD8+ cells as analyzed 
by FACS.  Bar graphs show proportion of cells e xpressing CD8 and CD38 markers in tissue samples pre and post Ab 
therapy in patient A and B.  
 
 STUDY RATIONALE  
Given that immunotherapeutic strategies, in particular immune checkpoint antibodies, focus on the 
generation of T -cell-based antitumor immunity, uptake of [18F]F-AraG within the tumor is 
hypothesized to correlate with T -cell mediated immune response seen in the biopsy samples of 
cancer patients treated with immune checkpoint blockade.  Correlation of pre - and post-treatment 
intratumoral immune in filtration by means of PET imaging will guide the development of future 

[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 16 of 43 clinical trials investigating the role of [18F]F-AraG in the monitoring of anti -tumor immune 
responses . Therefore, proper quantification of [18F]F-AraG  uptake in tumor lesions, and 
understanding its relation with physiologic uptake in background tissues is important. Note: 
checkpoint therapy in this study is standard- of-care and is not under investigation.  
The distribution of radiotracer activity depends on post -injection imaging time for both anatomical 
structures and pathologic processes. Anatomic structures with physiologic uptake and pathologic 
abnormalities are likely to be characterized by distinct time -activity curves  [3]. Therefore, the 
pharmacokinetic relationship between tumor activity and a variety of tissue background activity is 
important, which is best understood from dynamic images. Dynamic imaging of cancer subjects 
pre- and post -treatment  is expected to provide data to establish this relationship  between tumor 
and background, as well as the effect of treatment on the relationship .  
While u nderstanding t umor vs background activity in cancer patients  is important, such subjects 
are likely to have  prior or ongoing treatment , which may affect accurate baselining . Therefore, 
understanding normal tissue activity  in healthy volunteers in whom radiotracer distribution  is 
likely unencumbered by any effect of prior or ongoing treatment  can be important to establish 
baseline dynamic data . In addition, healthy volunteers are likely to tolerate the long dynamic scan 
better than cancer subjects, improving the chances of obtaining standard baseline data.      
Available PET/CT scanners can obtain dynamic images only on a portion of the body as large as 
their axial field of view, generally anywhere between 15 -30 cm. The 194 cm long uEXPLORER 
total- body PET scanner is the world’s first device to offer the ability to tomographically image all 
parts of the body simultaneously. Thus, the uEXPLORER PET/CT (now commercially available 
and with FDA 510(k) clearance) is the only scanner in the world capable of acquiring total -body 
dynamic images.  
In this pilot study, 2-4 healthy volunteers will undergo [18F]F-AraG dynamic imaging on the 
uEXPLORER total body PET/CT scanner to obtain preliminary data regarding pharmacokinetics 
and early biodistribution images. In addition, 2- 4 patients with NSCLC and planned for standard-
of-care PD-1/PD -L1 immunotherapy will undergo [18F]F-AraG dynamic imaging similarly on the 
uEXPLORER total body PET/CT scanner to obtain data regarding pharmacokinetics of the tracer 
in tumor lesions in the context of normal tissue uptake. An optional second similar scan will be performed 7-14 days after the first dose of immunotherapy to e xplore and document any treatment 
related changes in [
18F]F-AraG  uptake and kinetics. 
The study and data collected will be important to recommend an ideal time to acquire a whole body static scan using conventional and widely available PET/CT scanners for adequate tumor to background contrast and quantification, which in turn, will be essential for further clinical development of [
18F]F-AraG to aid  the monitoring of anti -tumor immune responses . 
 
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 17 of 43 
 OBJECTIVES  
The study is exploratory in nature with the following objectives: 
 Primary Objectives  
• To obtain preliminary data on the baseline whole -body pharmacokinetics of [18F]F-AraG  
physiologic uptake in various healthy tissues using the uEXPLORER PET/CT scanner. 
 
• To o btain preliminary data on the pharmacokinetics of [18F]F-AraG pathologic uptake in 
tumor lesions relative to  uptake in background tissues  in NSCLC subjects using the 
uEXPLORER PET/CT scan ner. 
  
• To recommend an ideal time window post [18F]F-AraG infusion to acquire static whole-
body scans using standard PET scanners used in clinical care. 
 Secondary Objectives  
• To assess [18F]-AraG uptake in NSCLC before and after the first dose of PD -1/PD- L1 
immunotherapy. 
 
 STUDY POPULATION 
 Inclusion Criteria  
Subjects are eligible if they meet ALL of the following criteria:  
For all subjects : 
1. Age ≥ 18 years.  
2. Ability to understand the purposes and risks of the trial and has signed an IRB-approved 
informed consent form.  
3. Willingness and ability to comply with all protocol required procedures.  
4. For men and women of child-producing potential, willingness to use of effective double barrier contraceptive methods during the study, up to 1 day after the last administration of the investigational product. 
For NSCLC subjects only: 
5. Patients with histologically confirmed advanced, locally advanced, or localized  NSCLC.  
6. Planned to undergo treatment with a PD-1 or PD-L1 inhibitor either as 1) monotherapy or 
as combination therapy with concurrent chemotherapy as treatment for advanced/metastatic disease 2) As consolidation therapy following chemoradiation for 
locally advanced disease or 3) As induction therapy either as monotherapy or combination therapy with chemotherapy prior to planned surgical resection 
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 18 of 43 7. At least 1 tumor lesion > 1 cm (cannot be only in liver) documented on CT or MRI or 
FDG -PET/CT (RECIST criteria 1.1 ; >1.5 cm for nodal lesions) within 45 days prior to 
scan date.  
8. Per investigator’s assessment  and in consultation with oncologists , at least one eligible 
lesion must be sufficiently separated from tissues with known high [18F]F-AraG  uptake, 
such as salivary glands, bladder, liver and kidneys so that quantification will be feasible.  
9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 
10. Meeting all clinical safety lab values per institution’s standard of care, or Investigator’s discretion, for patients receiving cancer treatment.  
 Exclusion Criteria  
Subjects are not eligible if they meet ANY of the following criteria:  
1. Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the 
investigator could compromise protocol objectives. 
2.  History of recent COVID -19 infection within the last 2 months OR history of COVID 
requiring hospitalization with lung injury at Investigator’s discretion 
3. Subjects with a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the scan 
4. Subjects receiving therapy with nucleoside analogs including but not limited to: acyclovir, valaclovir, penciclovir, famciclovir, ganciclovir, ribavirin, valganciclovir, glanciclovir 
5. Pregnant women or nursing mothers 
6. Body weight more than 240 kg (529 pounds) 
 
For NSCLC subjects only: 
7. Prior Treatment with anti -PD-1/PD-L1 immunotherapy. 
 
For Healthy subjects 
8. No primary care physician 
 
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 19 of 43 
 Subject recruitment  
4.3.1 NSCLC Subjects : 
Patients will be recruited by Dr. Daly and other physicians within the UC Davis Cancer Center 
from their clinics .  Dr. Daly  regularly sees lung cancer patients as part of her clinical practice.  
The physicians  will not be separately screening charts, but will recruit from among their  patients.   
 
4.3.2 Heal thy Subjects:  
Up to 4 normal subjects will be recruited by means of a flyer posted in specific areas: the Division 
of Nuclear Medicine (Davis Tower, Ambulatory Care Center (ACC)), the UC Davis Explorer Molecular Imaging Center located at 3195 Folsom Blvd, Sacramento, CA , the Radiology 
Academic office (ACC, Suite 3100), and the research laboratories of Dr. Simon Cherry and Dr. Jinyi Qi (Main campus, GBSF).  Flyers will be posted in other academic offices at ACC including 
cardiology, ophthalmology, orthopedics, etc. Additi onally, the study will be announced on the 
EXPLORER website: https://explorer.ucdavis.edu/  and on the UC Davis Clinical Study Pages site: 
https://studypages.com/ucdavis/  
 
 STUDY DESIGN  
Protocol CST -FARAG- 203 is a pilot study using the u EXPLORER total -body PET/CT system to 
acquire dynamic [18F]F-AraG scan data in healthy individuals and patients with NSCLC.  
Screening will consist of eligibility confirmation, the patient signing the consent form, and any 
assessments outlined in the study calendars below.  This will also include a query about status and 
date of COVID -19 vaccination.   
Eligible healthy subjects will undergo a single dynamic [18F]F-AraG PET/CT scan  (of duration up 
to 90- minutes) on the uEXPLORER PET/CT scanner  within 28 days of screening or on the day of 
screening if possible and convenient to the subject .  There will be a follow -up visit or call 7 days 
after the scan to assess any AEs that could be attributed to either the scan or the administration of [
18F]F-AraG . 
Eligible subjects with NSCLC who are planned to receive PD -1/PD -L1 immunotherapy will 
undergo a pre -therapy dynamic [18F]F-AraG PET/CT scan , and an optional post -therapy (first dose 
only) dynamic [18F]F-AraG PET/CT scan  on the uEXPLORER total -body scanner .  
For each enrolled patient, [18F]F-AraG will be administered by a licensed Nuclear Medicine 
technologist under the supervision of a board -certified Nuclear Medicine physician (ABNM or 
ABR certified) on an outpatient basis.  It will be administered as a single bolus injection of 5 mCi +/-20% IV into a vein. Vital signs will be assessed just prior to and after completion of dynamic 
[
18F]F-AraG PET scan.   
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 20 of 43 For each scan, the subject will be prepared according to the site’s standard procedures and asked 
to void the bladder immediately prior to imaging. For the scan, an intravenous (IV) line will be placed in a vein  and the subject will be positioned supine on the scanner table. The PET/CT 
imaging will begin with a low -dose CT scan  on the uEXPLORER PET/CT scanner. This CT 
scan will provide information for anatomic localization and attenuation correction purposes.  
[
18F]F-AraG  will then be infused as above and a 90 -minute dynamic PET scan will be performed 
on the u EXPLORER . The IV line will be removed after dynamic acquisition. For subjects who 
may not be able to undergo a 90-minute dynamic scan, a 60- minute dynamic PET scan will be 
performed, followed by a 10- minute static scan starting at 80 minutes post [18F]F-AraG  infusion. 
The separate static scan at 80 minutes will be obtained along with an ultra-low-dose CT which is 
needed  for attenuation correction  of this separate scan . 
The study will be an open label, non-randomized, single arm trial.  Patients and care providers will 
not be blinded to any part of the study.  
 Study Calendar  
Table 1: Study Schedule of Events (Healthy Volunteers)  
Protocol Assessments   Visit 11 Visit 21  
Screening  
(Day -28 to Day 0)  PET/CT scan  
(Day 0)  Safety Interview  
(Day 7)  
Informed consent  X   
Medical History and Physical Examination2 X   
Eligibility Assessment  X X  
Urine Pregnancy Tes t3 X X  
Concomitant medications  X X  
[18F]F-AraG PET/CT imaging   X  
Adverse events collection4  X X5 
1. Visits 1 & 2 can be merged into a single visit done on the same day.  
2. Includes vital signs, height, weight, BMI  
3. In women of 18-60 years old unless documented hysterectomy or bilateral ovarian removal is available.   
4. AE collection: Up to 2 hours of [18F]F-AraG infusion on Day 0; AEs that occur prior to this will be considered baseline .  
5. The follow up safety interview can be performed telephonically and does not require a separate in -person visit.  
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 21 of 43 Table 2: Study Schedule of Events (NSCLC subjects)  
 Visit 1  Visit 2  Visit 3 Visit 4Ψ  
Protocol Assessments  Screening  
(Day -28 
to Day 0)  PET/CT 
scan  
(Day 0)   (Day 0 -7) PET/CT 
(7-14 Days after 
V3) Safety Interview  
(7 days after last 
PET/CT scan ) 
Informed consent  X     
Medical history and Physical 
Examination2 X     
Eligibility Assessment (including 
eligible lesions assessment)  X X    
ECOG Performance Status 
Assessment  X     
SOC CT/MRI and/or FDG -PET/CT 
collection  X1     
Urine Pregnancy Test3 X X  X  
[18F]F-AraG PET/CT imaging   X  X  
Administration of PD -1/PD -L1 
Treatment    X   
Adverse events collection4  X  X X5 
Concomitant medications  X X  X  
1. CT or MRI  or FDG- PET/CT performed up to 45 days prior to Visit 2 is acceptable. 
2. Includes vital signs, height, weight, BMI  
3. In women 18-60 years old unless documented hysterectomy or bilateral ovarian removal is available  
4. AE collection: Up to 2 hours of [18F]F-AraG infusion on Visits 2 and 4 ; AEs that occur prior to this will be considered baseline. 
5. The follow up safety interview can be performed telephonically and does not require a separate in -person visit.  
Ψ Optional visit  
 
 Participant Duration 
Healthy volunteer subjects will have up to 3 visits over a period of one  to four  week s.  NSCLC 
patients will have up to 4 visits over a period of one to four weeks, prior to and after cancer 
treatment.   
We anticipate enrollment will be completed within 12 months after the start of enrollment and that 
the study will be completed in 2 years.   
 Participant Compensation 
Participants will be compensated $100 per PET/CT scan in the form of gift cards.  The maximum total will be $200 for NSCLC patients and $100 for healthy volunteers.   
 
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 22 of 43 
 MATERIALS AND METHODS  
 Study DRUG: [18F]F-AraG 
6.1.1 Manufacture  
[18F]fluoride (n.c.a.) in [18O]water is passed through a PS -HCO 3 cartridge, eluted with 1  mL of a 
phase transfer catalyst solution containing Kryptofix222 (15 mg) and K 2CO 3 3.5 mg) in 10:1 
acetonitrile/water.  The K222/K[18F]F complex is heated and dried under Helium at 65 °C for 
3 minutes, followed by heating at 95 ºC for 1  minute.  After cooling to ~50 ºC, a solution 
containing [18F]F-AraG trifylate precursor (6  mg in 1 mL DMSO) is added to the reactor and the 
solution heated to 115 °C for 45 minutes.  After cooling down to ~40 °C, to the reaction mixture 
was added so dium methoxide, and heated at 100 ºC for 10 minutes.  Reaction i s cooled to 40 ºC 
and after addition of 0.5 mL of 1  N HCl stirred at 95  ºC for 10 minutes.  The reaction mixture i s 
then cooled to 30 ºC and diluted with a solution of 0.5 mL of 1N NaHCO 3 in 9.5 mL of water 
(SV3). The solution in the reactor i s transferred through 4 ×  C-18 cartridges via a V31 valve and 
collected in a waste container.  The cartridges are  backwash ed to the reactor with 2  mL of methanol 
in the pre -HPLC tube.  Methanol i s removed under vacuum with the flow of helium at 90 ºC for 
13 minutes.  After cooling the reactor to 30 ºC water i s added and the solution transferred through 
a 0.45 µm filter into a pre -HPLC container.  
Crude  [18F]F-AraG is injected on to a HPLC Luna C18 semi -preparative reversed -phase column 
(5 µm, 10 ×  250 mm).  The desired product fraction (Rt ~ 16 minutes) is collected into  the round 
bottom flask pre -filled with 30  mL of water.  The diluted fraction is passed through the C18 plus 
cartridges and rinsed with water (10 mL), then the trapped product is  eluted by ethanol (1 mL) into 
a collection vial for subsequent dilution with saline (9 mL).  [18F]F-AraG for Injection is prepared 
by then passing through a  0.22 µm Millex GV sterile filter to a pre -assembled septum -sealed sterile 
collection vial (30  mL) for filtration and sterilization.  The final sterile empty vial, product needle, 
vent needle, 4 mm GV filter for vent and sterile GV filter (33  mm) are assembled in a sterile LFH 
(laminar flow hood).  The final product is released compliant to release specifications as submitted 
to the FDA . No further testing is required at the research site prior to injection. 
[18F]F-AraG  will be supplied by Cellsight at no cost to study patients.  
6.1.2 Availability  
The [18F]F-AraG will be synthesized, on a per scan basis, under cGMP at one of CellSight’s 
identified qualified production site s.  All qualified production sites are  FDA -approved clinical 
manufacturer s of the tracer. Cellsight carries the IND.  Cellsight submitted all the manufacturing 
CMCs to the FDA for all  approved site s.  As needed, the facility staff will be trained by Cellsight 
in synthesizing this radiopharmaceutical. Please refer to CellSight Pharmacy Manual.   
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 23 of 43 6.1.3 Agent Ordering  
The [18F]F-AraG will be individually requested per subject by Nuclear Medicine research 
coordinators or technologists, under the supervision of the Nuclear Medicine investigators, for 
synthesis under cGMP at  the identified production site . Please refer to CellSight Pharmacy 
Manual.   
6.1.4 Study Treatment Accountability  
The Investigator or designee will verify the contents of each shipment against the shipping 
documents. A study treatment accountability log will be kept by the Investigator to maintain current and accurate inventory records (batch, expiry, and quantity) covering the receipt, dispensing and the destruction of all the study treatments.  
At the conclusion of the study, or other situations as applicable (ex. site closure, IP expiry, etc.) 
the Investigator must agree to return or destroy all study materials as instructed by the Sponsor.  
Please refer to CellSight Pharmacy Manual.  
6.1.5 Dispens ing [
18F]F-AraG  
The [18F]F-AraG will be ordered and synthesized under cGMP at qualified sites  by radiochemistry 
staff in the Nuclear Medicine department.   
Each dose will be manufactured on a per patient, per scan basis, according to the investigator physician’s prescription order. Upon receipt, qualified personnel will ensure that the study drug is delivered in good condition, inventoried, stored properly, labeled and dispensed in compliance with the pharmacy manual, all regulatory agencies and per the investigator physician’s presc ription 
order.   
The [
18F]F-AraG dose will be measured by the qualified personnel in a dose calibrator prior to 
dispensing. Then the syringe will be placed in a shielded carrier for administration via venous infusion. After the dose administration, the qualified personnel will re turn the syringe for residual 
measurement by the nuclear medicine technologists  at the site. Measured radioactivity values and 
times of measurement will be documented, as well as the total injected volume.  
Regulatory agencies require accounting for the disposition of all investigational drugs received by 
each clinical site. Information on drug disposition required by law consists of the date received, date dispensed, quantity dispensed, and the patient ident ification number to whom the drug was 
dispensed. The Investigator is responsible for accounting for all unused study drug and destroying all used study drug containers in compliance with the pharmacy manual.  
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 24 of 43 
 uEXPLORER PET/CT Scan  
For the purpose of this study, [18F]F-AraG  PET/CT scan images must only be acquired on the 
uEXPLORER scanner and that scanner must undergo regular Quality Control (QC) checks. 
Documentation of such QC activities must be available upon request or audit. Image acquisition will be obtained in l ist mode and the raw data saved to allow for virtual radioactive dose 
reconstruction at a later date.  
 
 RISKS TO SUBJECTS  
7.1.1 Risks from [18F]F-AraG  PET/CT scan  
In this study, 2-4 healthy subjects and 2- 4 NSCLC  patients will undergo research PET/CT imaging 
with [18F]F-AraG as specified in the experimental imaging section.  [18F]F-AraG PET imaging has 
been performed on 6 healthy volunteers in a separate study with no drug- related side effects.   In 
addition, [18F]F-AraG has been administered to 13 cancer  patients with 7 of those  patients getting 
two doses for pre and post immunotherapy scans, also without any drug- related side effects.  
Given the prior clinical safety experience  thus far , we expect few , if any, adverse effects  from  
[18F]F-AraG  administration in this study . Presently there are no standard surrogate biomarkers  or 
imaging modalities that can substitute for these procedures.  The alternative will be for the patient to withdraw from the imaging study.   
The safety monitoring practices employed by this protocol are adequate to protect the subjects’ 
safety and should detect all Treatment Emergent Adverse Events (TEAEs). An indirect health 
benefit to the subjects enrolled in this trial is the free medical te sts received at screening and during 
the study. 
Due to the (up to) 90- minute long scan time through which the participants are expected to remain 
still, the patients may feel discomfort and/or fatigue from laying on the scanner table. In addition, 
they may experience claustrophobia from being inside the  scanner bore, which is a partially 
enclosed space.  
Another risk is possible bruising and/or infection at the IV site . 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 25 of 43 Reproductive Risks are associated with PET: (PET) radiotracers studies on the fetus (unborn child) 
have not been done. To avoid risk to the fetus, it is important that female participants not become pregnant while they are participating in this research st udy. Avoiding sexual activity is the only 
certain method to prevent pregnancy. However, if they choose to be sexually active, they should use an appropriate “double barrier” method of birth control (such as female use of a diaphragm, intrauterine device (I UD), or contraceptive sponge, in addition to male use of a condom) or the 
female should be using prescribed “birth control” pills, injections, or implants. Such birth control methods should be used for as specified by their doctor prior to beginning their participation in the research study and continues for as long as specified by their doctor after their final study visit. If they choose to be sexually active during this study, even with the use of these birth control measures pregnancy could still result . The risks of participation in the research PET studies while 
pregnant include potential loss of pregnancy or possible birth defects. If participant is a woman 18-
60 years old, they will undergo a urine pregnancy test within 24 hours prior to each PET session unless documented hysterectomy or bilateral ovarian removal is available . If participant becomes 
aware that they are pregnant during the course of their participation in this study, they should contact immediately the study doctor . 
It is possible that uEXPLORER PET/CT scans may detect false positive findings that may 
require further follow -up (clinical, imaging  or surgical) with all the risks associated with these 
follow -up procedures.  The PET/CT images created for this study are for research and are not 
meant to evaluate subject health, as they would be if they were part of a clinical (non- research) 
visit to the doctor or hospital. The images will not receive any routine clinical review  by 
radiologists who interpret PET/CT scans. This means that some findings may be overlooked or 
misinterpreted.  However, if the PET/CT technologists do notice findings that caus e concern, 
they will notify the Study Radiologist.   Additionally, if a member of the research team notices 
any findings that cause concern while conducting image review for study purposes, they will notify the Study Radiologist. The Study Radiologist will  conduct a brief review of part of the 
study images for quality purposes.   If the Study Radiologist thinks a clinical problem is present, one of the IRB -approved study physicians will discuss these possible problems with the subject 
within 8 weeks or imme diately upon recognition of any critical finding that requires immediate 
and/or urgent intervention as described in the Department of Radiology Critical Findings policy (full dataset of images are sometimes not available for review in less than 3 days).  U pon written 
request, we will provide the subject with a copy of a subset of their CT images to take to the 
physician of their choosing. A subset of PET images may also be shared with the subject unless 
the images from the study are clinically uninterpretab le. In addition, the sponsor may restrict 
sharing of PET images due to the nature of the research protocol or to protect intellectual property (e.g. proprietary radiotracers). We will send a standard letter to the designated licensed medical provider ident ified by the subject, unless one of the study physicians is part of the 
subject’s care.  The standard letter will state that (i) the subject’s images were acquired exclusively for a research study and incidental findings that may be related to a medical condition were observed by a UC Davis radiologist; (ii) the images did not receive any dedicated 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 26 of 43 routine clinical review and findings may have been overlooked or misinterpreted; (iii) the 
subject’s physician can contact the study doctor at any time if there are any concerns regarding the study or the subject’s findings.  
7.1.2 Radiation Risk  
Each patient will receive up to two 5 mCi +/- 20% doses of [
18F]F-AraG.   Dosimetry assessment 
estimated an effective dose of 0.58 and 0.62 mSv/mCi for males and females, respectively.  Risks 
from the PET/CT itself include additional radiation exposure from the CT attenuation correction scan ( estimated to be 10  mSv for each low dose CT scan and 1 mSv for each ultra low dose CT 
scan). The table below shows the estimated effective radiation dose received by the subjects in this 
protocol:  
 Healthy Subjects  NSCLC Patients  NSCLC Patients who 
cannot undergo 90 
minutes continuous 
scanning  
Low dose CT scan  10 mSv  10 mSv  10 mSv  
Ultra low dose CT scan  N/A N/A 1 mSv  
[18F]-AraG PET scan  2.9 +/ - 0.29 mSv(male)  
3.1 +/ - 0.31 mSv(female)  2.9 +/ - 0.29 mSv(male)  
3.1 +/ - 0.31 mSv(female)  2.9 +/ - 0.29 mSv(male)  
3.1 +/ - 0.31 mSv(female)  
Total estimated dose  12.9 +/ - 0.29 mSv(male)  
13.1 +/ - 0.31 mSv(female)  12.9 +/ - 0.29 mSv(male)  
13.1 +/ - 0.31 mSv(female)  13.9 +/- 0.29 mSv(male)  
14.1 +/- 0.31 mSv(female)  
Number of scans  1 2 2 
Maximum estimated 
dose  13.2 mSv (male)  
13.4 mSv (female)  26.4 mSv (male)  
26.8 mSv (female)  27.4 mSv (male)  
27.8 mSv (female)  
 
The total estimated dose from the combined PET/CT examination will be 13.4 mSv or less  for 
normal subjects and 27.8 mSv or less for patients with NSCLC . The use of radiation involves 
minimal risk and is required to obtain the desired research information. 
 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 27 of 43 
 POTENTIAL BENEFITS TO SUBJECTS  
There will be no direct benefit to the subjects.  The therapy for NSCLC Subjects will not be 
changed based on the [18F]F-AraG PET findings.   
 CONCOMITANT MEDICATIONS   
Subjects must be questioned at each study visit concerning any new medications or changes in current medications including over -the-counter and topical medications. All medications and 
therapies administered or taken by the subject beginning 30 days prior to signing the ICF and throughout the study will be recorded in the source documents and on the appropriate page of the CRF. Intravenous fluid documentation will NOT include IV fluids used to administer medications, only the medications administered through the IV fluid will be documented. Intravenous fluids used to keep the vein open or used for flushing will also not be documented in the concomitant medication CRF.  
For each medication and non- study treatment, the following will be documented:  
 Medication/treatment name (generic name may be used if trade name is unknown)  
 Dose, unit, and frequency of dosing (individual dosages, not total daily dose). Note: Each 
new dose of medication should be recorded as a separate entry, with the exception of medications that are given on a sliding scale. For these, it is acceptable to en ter the range 
of the dosage, including the start and stop dates for which the specified dosage range was used. 
 Route of dosing 
 Indication for use (Indication should include exact medical terminology)  
 The start date  
 The stop date (if medication/therapy is not ongoing)  
 
 OUTCOME MEASURES AND ANALYSIS  
 Physiological Time -Activity Curves of [18F]F-AraG Uptake within Healthy Tissues  
One of the primary objectives of the study is to obtain baseline pharmacokinetic information in 
the form of [18F]F‑AraG uptake in healthy tissues as a function of time. To achieve this outcome, 
data on [18F]F‑AraG uptake in several tissue types will be collected from healthy subjects. This 
data will be presented in the form of time -activity curves (TAC) generated for each tissue type.   
 Time -Activity Curves of [18F]F-AraG Uptake within Tumors and Background 
Tissues  
Another  objective  of the study is to obtain pharmacokinetic information in cancer subjects  in the 
form of relative [18F]F-AraG uptake in tumor lesions and background tissues as a function of time. 
To achieve this outcome, data on [18F]F-AraG uptake in tumor lesions and background activity in 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 28 of 43 the same  tissue s as in Section 10.1 will be collected . This data will be similarly presented in the 
form of time -activity curves (TAC) generated for each tissue type as in Section  10.1, as well as for 
tumor lesions against their background tissues . 
 Recommended time post [18F]F-AraG infusion to acquire a single static PET/CT 
scan  
The TAC analysis of [18F]F-AraG uptake will provide insight into the earliest time to achieve 
adequate tumor versus non- malignant background tissue activity, as well as time to reach and 
remain in steady state up to 90 minutes. Such information can guide a recommendation for the  
ideal time window for a static [18F]F-AraG PET scan for future trials and potential clinical use.  
 Change in PET signal pre - and post - first dose of PD -1/PD -L1 immunotherapy  
For NSCLC subjects who undergo two [18F]F-AraG PET/CT scans, the signal at a static time point 
post [18F]F-AraG infusion (obtained from the result of one of the outcome measures; Section 10.3) 
from both scans will be observed for trends.  
 Safety Outcome Measures  
• Incidence of Treatment -Emergent Adverse Events (AEs).  
• Incidence of withdrawals due to AEs. 
• Serious Adverse Events (SAEs)  
Analyses of safety outcomes will be conducted using the safety population. Adverse events will 
be coded using MedDRA. Treatment Emergent AE’s (TEAE) are defined as events with an onset on or after the first treatment. TEAEs will be summarized by treatment group and by stage of the study, System Organ Class, and preferred term. The following TEAE summaries will be provided:  
• TEAEs by severity grade  
• TEAEs by relationship to study treatment. 
In addition, separate summaries of serious adverse events, and adverse events resulting in discontinuation of study treatment will be presented. 
 Efficacy Outcome Analysis  
Descriptive statistics will be used to summarize the characteristics of study participants, including their age, gender, primary tumor sites and clinical stages, concomitant medications, etc.  Frequency tables will be used to summarize categorical variables.  Median and inter -quartile ranges wi ll be 
used to describe no- normally distributed continuous variables.  Mean and standard deviation will 
be used to summarize normally distributed continuous variables.  
Feasibility will be assessed per patient basis.  The percentage of patients who can be successfully evaluated by [
18F]F-AraG PET imaging will be computed and summarized. 
 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 29 of 43 
 STATISTICAL METHODS AND DATA ANALYSIS  
 Number of Subjects  
The primary goal of this pilot study is  to acquire preliminary  dynamic [18F]F-AraG scan data in 
healthy individuals and patients with NSCLC. Given the preliminary nature of this study, a power 
calculation was not performed. 2- 4 subjects are likely sufficient for a general understanding of 
healthy tissue uptake as a function of time. Similarly, 2- 4 NSCLC subjects are considered adequate 
to provi de at least one lesion with positive and sufficient tumor uptake of [18F]F-AraG to provide 
a general understanding of tumor tracer kinetics.  
 Scan Data 
Data from uEXPLORER scanner will be acquired in listmode. Data will be reconstructed using 
manufacturer’s recommendations. Image quality, quantitative comparisons and preliminary biodistribution data collection will be performed by means of volumes of interest (VOIs) drawn in differe nt organs, tissue types and tumor lesions (in NSCLC subjects). These will be used to 
generate standard uptake values, normalized to body weight (SUV -bw) for the purpose of 
quantitative analysis of spatial as well as temporal tracer distribution . 
 General Statistical Considerations  
All collected study data will be presented in subject data listings. Descriptive statistics (n, mean, 
standard deviation, median, minimum and maximum) will be presented for continuous variables. 
Frequencies and percentages will be presented for categorical  variables.  
 Analysis populations  
The details of the analysis population to be used for the study are described below:  
11.4.1 Efficacy population  
The efficacy population is defined as all subjects who have received at least one (up to) 90-minute dynamic [
18F]F-AraG  PET scan.  
11.4.2 Per-protocol (PP) Population  
The Per Protocol (PP) population is defined as the set of subjects who meet the efficacy population requirements and were not associated with a major protocol violation.     
11.4.3 Safety Population  
The Safety population is defined as all subjects receiving at least one dose of [
18F]F-AraG .    
 Statistical Methods  
11.5.1   Subject Disposition  
The disposition of all subjects who sign an ICF will be provided. The numbers of subjects screened, 
enrolled, completed, and discontinued during the study, as well as the reasons for all post -
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 30 of 43 enrollment discontinuations will be summarized for healthy and NSCLC subjects respectively. 
Disposition and reason for study discontinuation will also be provided as a by- subject listing.   
11.5.2   Demographics and baseline characteristics analysis  
Demographics and baseline characteristics will be summarized for healthy and NSCLC subjects respectively using appropriate descriptive statistics.  
11.5.3   Concomitant Medications/Therapies  
Concomitant medications/therapies will be summarized separately for the Safety population. All prior and concomitant medications recorded in the case report form will be coded to all matching 
Anatomic Therapeutic Classification codes using the most recent version of WHO Drug. 
Descriptive summaries, by study group and stage of the study, will be prepared using the coded 
term. All concomitant medications/therapies recorded in the case report form will be listed.   
11.5.4   Medical history  
The medical history will be summarized and/or listed descriptively.  
11.5.5  Study Treatment Compliance  
The study treatment compliance data will be summarized and/or listed descriptively.  
 
 SAFETY REPORTING OF ADVERSE EVENTS  
 Assessment of Safety  
The Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE or SAE, as provided in this protocol.  During the study when there is a 
safety evaluation, the Investigator or site staff will be res ponsible for detecting, documenting and 
reporting AEs and SAEs as detailed in this Section of the protocol.  
 Adverse Events  
An adverse event (AE) is defined as any unfavorable or unintended sign, symptom, or disease that 
occurs or is reported by the patient to have occurred, or a worsening of a pre -existing condition.  
An adverse event may or may not be related to the study tre atment.  
AEs will be elicited through direct questioning and subject reports. Any abnormality in physical 
examination findings or laboratory results that the investigator believes is clinically significant to 
the research subject and that occurred after initiation of the first study treatment will be reported 
as AEs. Abnormal findings that are NOT clinically significant should not be recorded as an AE.  
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 31 of 43 
 Reporting of Adverse Events  
Report initiation for all AEs and serious adverse events (SAEs) will begin immediately after the 
first infusion of [18F]F-AraG (Visit 2) and continue until the Day 7 follow up. The Day 7 adverse 
event assessment may be telephonic and does not require an office visit. All events will be followed to resolution or until they are considered to be not clinically significant according to the investigator’s judgment.   
All AEs must be recorded in the subject’s medical records and on the CRF. AEs will be reported 
using customary medical terminology along with the following information:  the onset and end dates, whether the event is at the site of [
18F]F-AraG administration, whether the event is 
considered to be a SAE, the impact the event had on study treatment, the CTCAE grade (intensity) 
of the event, the causality of the event, whether treatment was given as a result of the event, and 
the outcome of the event.  
Serious Adverse Events 
An AE should be classified as an SAE if any of the following criteria are met: 
• It results in death (i.e., the AE actually causes or leads to death).  
• It is life threatening (i.e., the AE, in the view of the investigator, places the subject at 
immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death.). 
• It requires or prolongs inpatient hospitalization. 
• It results in persistent or significant disability/incapacity (i.e., the AE results in 
substantial disruption of the subject’s ability to conduct normal life functions). 
• It results in a congenital anomaly/birth defect in a neonate/infant born to a mother 
exposed to the investigational treatment. 
• It is considered a significant medical event by the investigator based on medical judgment (e.g., may jeopardize the subject or may require medical/surgical intervention to prevent one of the outcomes listed above).  
 Methods and Timing for Assessing and Recording Safety Variables  
The investigator is responsible for ensuring that all AEs and SAEs that are observed or reported 
during the study are collected and reported to the FDA in accordance with CFR 312.32 (IND Safety Reports).  
 Assessment of Adverse Events  
All AEs and SAEs whether volunteered by the subject, discovered by study personnel during questioning, or detected through physical examination, laboratory test, or other means will be reported appropriately. Each reported AE or SAE will be described by its duration (i.e., start and 
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 32 of 43 end dates), regulatory seriousness criteria if applicable, suspected relationship to the 
investigational treatment (see following guidance), and actions taken. 
The guidelines outlined in CTCAE v5.0 will be used for assessing the intensity of the event. The 
general guidelines for assessing the AE grade appear below.  Full guidelines may be obtained at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf  
 
Table 3: CTCAE v5.0 General Guidelines  
Grade  Description  
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living (ADL)*.  
Grade 3  Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self care ADL†.  
Grade 4  Life-threatening consequences; urgent intervention indicated.  
Grade 5  Death related to AE.‡  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.  
†Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.  
‡Unlike the AE outcome assessment (see Section Error! Reference source not found.), a subject may have more than one 
Grade 5 event.  
 
-Common Terminology Criteria for Adverse Events (CTCAE), v5.0: November 27, 2017 
 
 Causality 
Adverse events will be assigned a relationship (causality) to the study treatment.  The Investigator 
will be responsible for determining the relationship between an AE and the study treatment.  The 
type of event, organ system affected, and timing of onset of the event will be factors in assessing 
the likelihood that an AE is r elated to the study treatment.  Relationship of AEs to study treatment 
will be classified as follows: 
 Not Related :  No relationship exists between the AE and the treatment.  The event is 
attributed to a pre -existing medical condition or an intercurrent event unrelated to the 
study product. 
 P ossibly Related :  Follows the treatment but may have developed as a result of an 
underlying clinical condition or treatments/interventions unrelated to the study product. 
 P robably Related :  Follows the treatment but is unlikely to have developed as a result 
[18F]F-ARAG/NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 33 of 43 of the subject’s underlying clinical condition or other treatment or other interventions. 
 Definitely Related :  Follows the treatment and physical evidence shows a convincing 
relationship to the treatment.  
 
 Reporting Requirements for SAEs  
The Investigator is required to report all SAEs.  Once the Investigator becomes aware of an SAE, 
he/she must report the SAE to CellSight within 24 hours at: 
Phone: 650-799-1589 Email: adverse.events@cellsighttech.com  
 
The CellSight Medical Monitor may request additional supporting documentation as it becomes 
available, such as lab reports, ECG reports, discharge summary, hospital notes, etc.  
The Investigator is also responsible for reporting all SAEs to the appropriate Institutional Review 
Board (IRB) in accordance with local laws and regulations. The Investigator is responsible for 
maintaining documentation in the study file that indicates the IRB has been properly notified. Under 21 CFR 312.32(c), the sponsor is required to notify FDA and all participating investigators in an IND safety report (i.e., 7- or 15- day expedited report) of potentially serious risks from clinical 
trials or any other source as soon as possible, but no later than 15 calendar days after the spons or 
receives the safety information and determines that the information qualifies for reporting. Participating investigators include all investigators to whom the sponsor is providing drug under any of its INDs or under any investigator’s IND (21 CFR 312.32(c)(1)).  
 
 QUALITY CONTROL AND QUALITY ASSURANCE  
 Monitoring Requirements  
In an effort to fulfill the obligations outlined in 21 CFR Part 312 and ICH guidelines which require 
the Sponsor to maintain current personal knowledge of the progress of a study, the Sponsor's designated monitor will visit the center(s) during the study a s well as maintain frequent telephone 
and written communication. The Investigator will permit the Sponsor to monitor the study as frequently as is deemed necessary and provide access to medical records to ensure that data are being recorded adequately, tha t data are verifiable and that protocol adherence is satisfactory.  
The Investigator will permit representatives of the Sponsor and/or designated CRO to inspect all CRFs and corresponding study subject original medical records (source documents) at regular intervals throughout the study. Subject original medical records and other relevant data must be 
available to support all data recorded in the CRF. In addition to the original medical records, these 
data may include but are not limited to, study, laboratory and diagnostic reports, wound images and tracings, etc.  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 34 of 43 Site inspections serve to verify strict adherence to the protocol and the accuracy of the data being 
entered on the CRFs, in accordance with federal regulations. A Monitoring Log will be maintained at each study site that the monitor will sign, date, and s tate the type of visit.  
The Investigator should be aware that the study site and subject records may be inspected by the Sponsor and or representatives of the designated CRO, FDA, or other regional regulatory authority. 
 Acceptability of Case Report Forms  
All CRFs will be completed as soon as possible after the subject's visit. Corrections to data on the 
CRFs will be made according to standard data correction procedures. The Investigator will review 
CRFs to indicate that, to his/her knowledge, they are complete and accurate. CRFs may be reviewed by the Sponsor’s or designated CRO’s monitor, who will make a decision as to their acceptability.   
 Modification of Protocol  
The Investigator will not modify or alter this protocol without first obtaining the concurrence of the Sponsor. Approval by the Investigator’s IRB must also be obtained prior to implementation of the change, with two exceptions:  
1. When necessary to eliminate apparent immediate hazard to the subject; or  
2. When the modification does not involve the subject’s participation in the trial. 
An amendment may also require modification of the ICF. The Investigator will provide an approval letter for the amendment and revised ICF, if applicable, to the Sponsor. An amendment must be in writing and dated by both the Sponsor and the Investigator. If necessary, the Sponsor will submit protocol amendments to FDA and other appr opriate regulatory authorities. 
 Reporting Protocol Deviations  
The Investigator is obligated to follow the protocol without departure from the requirements written in the protocol. If the Investigator deems a deviation from the protocol requirements is necessary for a particular subject, the Sponsor will be notified a nd consulted prior to the subject’s 
continuation in the study. The Sponsor also has the right to discontinue the subject for protocol violations. The IRB may also have to be contacted if safety to the subject or if the scientific soundness of the study is involved. All protocol deviations must be documented in the CRFs. 
 Subject Premature Withdrawal from Study  
A subject who is enrolled into the study but does not complete the study will be considered prematurely discontinued.  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 35 of 43 All subjects have the right to withdraw at any point during the study without prejudice. It will be 
documented whether or not each subject completed the clinical study. If, for any subject, study treatment or observations were discontinued, the reason(s) w ill be recorded and the Sponsor should 
be notified promptly. All efforts must be made to collect data and report records and test results as completely as possible. Reasons for subject withdrawal/discontinuation may constitute one of the following:  
 
• Subject withdrew consent  
• Subject chooses to withdraw from study 
• Subject is withdrawn due to an AE  
• Pregnancy  
• Lost to follow -up  
• The Investigator determines that it is in the subject’s best interest 
• Excessive protocol deviations, as determined by the Investigator  
• Discontinuation of study by the Sponsor  
Important Notes:  
1. Subjects may drop out or be withdrawn at their own request. Although subjects do not need 
to give a reason for requesting withdrawal from the trial, the Investigator should make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. 
2. Any subjects reporting Serious Adverse Events (SAEs) that have not resolved by their last 
study visit will be followed to resolution or until 30 days after the subject completes the study. 
3. Every attempt should be made to collect follow -up information. The reason for withdrawal 
from the study (if known) will be recorded in the source documents and on the appropriate page 
of the CRF.  
4. Before a subject is identified as lost -to-follow -up, the site should make all reasonable 
efforts to contact the subject. These attempts must be documented and should include at a minimum one phone call and one follow -up certified letter.  
 
 DATA AND SAFETY MONITORING COMMITTEE  
In addition to the requirements for adverse event reporting as outlined in Section 11.0, this protocol is also subject to the UC Davis Cancer Center’s (UCDCC) Data and Safety Monitoring Plan. The UCDCC is committed to pursuing high- quality patient -oriented clinical research and has 
established mechanisms to ensure both scientific rigor and patient safety in the conduct of clinical 
research studies. The UCDCC relies on a multi -tiered committee system that reviews and monitors 
all cancer clinical trials and e nsures the safety of its participants, in compliance with institutional 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 36 of 43 and federal requirements on adverse event (AE) reporting, verification of data accuracy, and 
adherence to protocol eligibility requirements, treatment guidelines, and related matters. The Scientific Review Committee (SRC) assumes overall oversight of cancer studies, with assistance and input from two independent, but interacting, committees: the Quality Assurance Committee and the Data and Safety Monitoring Committee. A multi -level review system strengthens the 
ability of the UCDCC to fulfill its mission in  conducting high quality clinical cancer research.  
According to the UCDCC Data and Safety Monitoring Plan, any new serious adverse events related to the drugs being used on this trial are reviewed monthly by the UCDCC Data and Safety Monitoring Committee and any applicable changes to the study are recommended to the PI, if 
necessary.  
The UCDCC SRC determines if a UCDCC Data and Safety Monitoring Board (DSMB) is 
required.  If required, the Data and Safety Monitoring Committee will appoint a DSMB. The 
DSMB is responsible for reviewing study accrual logs, adverse event information and dos e 
escalation meeting minutes (where applicable) to ensure subject safety and compliance with protocol defined guidelines. 
Results of the DSMC audit will be communicated to CellSight, IRB and the appropriate regulatory 
authorities at the time of continuing review, or in an expedited fashion, as needed.  
 
 ETHICAL CONSIDERATIONS AND ADMINISTRATIVE PROCEDURES  
 Ethics and Good Clinical Practice  
This study must be carried out in compliance with the protocol and Good Clinical Practice, as described in:  
1. ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996.  
2. Directive 91/507/EEC, The Rules Governing Medicinal Products in the European Community.  
3. US 21 Code of Federal Regulations dealing with clinical studies (including parts 50 and 56 concerning informed consent and IRB regulations). 
4. Declaration of Helsinki, concerning medical research in humans (Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996). 
The investigator agrees, when signing the protocol, to adhere to the instructions and procedures 
described in it and thereby to adhere to the principles of Good Clinical Practice that it conforms 
to. 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 37 of 43 
 IND Holder Information  
CellSight Technologies is the holder of the IND (IND# 123591) .  The company is sponsoring this  
clinical trial and is responsible for the imaging costs incurred in the trial. The radiotracer will be 
manufactured under the direction of CellSight Technologies at a qualified production site . 
 Institutional Review Board/Independent Ethics Committee  
Before implementing this study, the protocol, the proposed informed consent form and other 
information to subjects, must be reviewed by a properly constituted Institutional Review Board Committee (IRB). A signed and dated statement that the protocol and informed consent have been approved by the IRB must be given to Cellsight before study initiation. Any amendments to the protocol, other than administrative ones, must be approved by this committee.  
 Informed Consent  
The investigator must explain to each subject (or legally authorized representative) the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits involved and any discomfort it may entail. Each subj ect must be informed that 
participation in the study is voluntary and that he/she may withdraw from the study at any time and that withdrawal of consent will not affect his/her subsequent medical treatment or relationship 
with the treating physician. 
This informed consent should be given by means of a standard written statement, written in non -
technical language. The subject should read and consider the statement before signing and dating 
it and should be given a copy of the signed document. If the subject cannot read or sign the 
documents, oral presentation may be made or signature given by the subject’s legally appointed 
representative, if witnessed by a person not involved in the study, mentioning that the patient could not read or sign the documents . No patient can enter the study before his/her informed consent has 
been obtained.  
The method of obtaining and documenting the informed consent and the contents of the consent will comply with ICH -GCP and all applicable regulatory requirement(s).  In accordance with UCD 
policy an original signed and dated participant Informed Consent doc ument will reside in a secured 
location within the department of radiology. Copies of the signed and dated Informed Consent document will be provided to the study participant and UCD Health System Information Management for inclusion in the participant’s U CD Health System Medical Record.  
The informed consent form is considered to be part of the protocol and must be submitted by the investigator with it for IRB/IEC/REB approval.  
Women of child bearing potential should be informed that taking the study drug may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirement for the duration of the 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 38 of 43 study. If there is any question that the patient will not reliably comply, they should not be entered 
in the study. 
 Sharing of Results with Subjects  
The results of this research will not be shared with subjects. However, results may be shared as described in Section 7.1.1. 
 Disclosure and Confidentiality  
☒ I understand that if this study involves the use of  the UC Davis Health Electronic Health Record 
(EMR/EPIC) it also contains the clinical data for Marshall Medical Center (MMC). I understand 
that MMC patient data cannot be accessed for research purposes and that I must take the necessary steps to ensure that MMC data is not accessed, used, or disclosed for UC Davis Health research 
purposes.  
In order to  maintain patient privacy, all study reports and communications will identify the patient 
by initials and the assigned patient number.  Data capture records and drug accountability records 
will be stored in secure cabinets in the department of radiology. M edical records of patients will 
be maintained in strict confidence according to legal requirements.  The patient’s confidentiality will be maintained and will not be made publicly available to the extent permitted by the applicable laws and regulations.
 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinica l information relating to participants. Therefore, 
the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third pa rty without prior written approval of the sponsor. 
The study monitor, other authorized representatives of the sponsor, representatives of the IRB or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
The study participant’s contact information will be securely stored at the  clinical site for internal 
use during the study. At the end of the study, all records will continue to be kept in a secure location 
for as long a period as dictated by local IRB and Institutional regulations.  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be stored according to IRB approved specifications , and will be transmitted to  the Sponsor . 
This will not include the participant’s contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by Sponsor  research 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 39 of 43 staff will be secured and password protected. At the end of the study, all study databases will be 
de-identified and archived as per IRB approved specifications . 
 Declaration of Helsinki 
The investigator must conduct the trial in accordance with the principles of the Declaration of Helsinki. Copies of the Declaration of Helsinki and amendments will be provided upon request or can be accessed via the website of the World Medical Association  at 
http://www.wma.net/e/policy/17 -c_e.html . 
 Compensation for Research -Related Injury  
If a subject is injured as a result of being in this study, the University of California will provide necessary medical treatment.  Depending on the circumstances, the costs of the treatment may be covered by the University or the study sponsor or may be billed to the subject’s insurance company just like other medical costs.  The University and the study sponsor do not normally provide any other form of compensation for injury.  
 Economic Burden to Subjects  
All study -related procedures will be paid by the study and not charged to the subject.  
 
 
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 40 of 43 
 REFERENCES  
1. Brinkman, J.A., Fausch, S.C, Weber, J. S., Kast, W. M. (2004) Peptide -based vaccines for 
cancer immunotherapy, Expert Opinion on Biological Therapy, 4:2, 181- 198, DOI: 
10.1517/14712598.4.2.181 
2. Castaldi, P., et al., Role of F -18-FDG PET -CT in head and neck squamous cell carcinoma. 
Acta Otorhinolaryngologica Italica, 2013. 33(1): p. 1- 8. 
3. Chan, I. T., Limmer, A., Louie, M. C., Bullock, E. D., Fung- Leung, W. P., Mak, T. W., & 
Loh, D. Y. (1993). Thymic selection of cytotoxic T cells independent of CD8 alpha -Lck 
association. Science, 261(5128), 1581- 1584.  
4. Dal Bello, M.G., et al., Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discov Today, 2017. 22(8): p. 1266- 1273. 
5. Dallal, R.M. and M.T. Lotze, The dendritic cell and human cancer vaccines. Current Opinion in Immunology, 2000. 12(5): p. 583- 8. 
6. Davis, M.M., et al., Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem, 2003. 72: p. 717- 42. 
7. DeAngelo, D. J. (2009). Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Hematology/Oncology 
Clinics of North America,  
11. Volume 23, Issue 5,2009,Pages 1121- 1135, https://doi.org/10.1016/j.hoc.2009.07.008. 
8. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228- 247. doi:10.1016/j.ejca.2008.10.026  
9. Franc BL, Goth S, MacKenzie J, et al. In Vivo PET Imaging of the Activated Immune 
Environment in a Small Animal Model of Inflammatory Arthritis. Mol Imaging. 2017;16:1536012117712638. doi:10.1177/1536012117712638 10. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T -
cell response. Nat Rev Immunol. 2005 Nov;5(11):844- 52. Review. doi: 10.1038/nri1710 
11. Gilardi, L., et al., Ipilimumab- Induced Immunomediated Adverse Events: Possible Pitfalls in 
18F -FDG PET/CT Interpretation. Clinical nuclear medicine, 2014. 39(5): p. 472- 4. 
12. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711- 723. doi:10.1056/NEJMoa1003466 
13. Kantoff, P.W., et al., Sipuleucel -T Immunotherapy for Castration- Resistant Prostate Cancer. 
New England Journal of Medicine, 2010. 363(5): p. 411- 422. 
14. Levi J, Lam T, Goth SR, et al. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti -PD-1 Therapy. Cancer Res. 2019;79(13):3455–3465. doi:10.1158/0008-
5472.CAN -19-0267  
15. Mayordomo, J.I., et al., Bone marrow -derived dendritic cells pulsed with synthetic tumour 
peptides elicit protective and therapeutic antitumour immunity. Nat Med, 1995. 1(12): p. 1297-302. 16. Mayordomo, J.I., et al., Therapy of murine tumors with p53 wild- type and mutant sequence 
peptide -based vaccines. J Exp Med, 1996. 183(4): p. 1357- 65. 
 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 41 of 43  
17. Nair -Gill E, Wiltzius SM, Wei XX, et al. PET probes for distinct metabolic pathways have 
different cell specificities during immune responses in mice [published correction appears in J Clin Invest. 2010 Jul 1;120(7):2641]. J Clin Invest. 2010;120(6):2005–2015. doi:10.1172/JCI41250 
18. Namavari, M., Chang, Y., Kusler, B. et al. Synthesis of 2? -Deoxy -2?-[
 18F]Fluoro -9-?-D-
Arabinofuranosylguanine: a Novel Agent for Imaging T -Cell Activation with PET. Mol Imaging 
Biol 13, 812–818 (2011). https://doi.org/10.1007/s11307- 010-0414- x 
19. Nishino, M., et al., Developing a Common Language for Tumor Response to 
Immunotherapy: Immune -Related Response Criteria Using Unidimensional Measurements. 
Clinical Cancer Research, 2013. 19(14): p. 3936-  3943. 
20. Novellino, L., C. Castelli, and G. Parmiani, A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother, 2005. 54(3): p. 187- 207 
https://doi.org/10.1007/s00262- 004-0560- 6 
21. Radu CG, Shu CJ, Nair -Gill E, et al. Molecular imaging of lymphoid organs and immune 
activation by positron emission tomography with a new [
18F ]-labeled 2' -deoxycytidine analog. 
Nat Med. 2008;14(7):783–788. doi:10.1038/nm1724 22. Ribas, A. and J.D. Wolchok, Cancer immunotherapy using checkpoint blockade. Science, 2018. 359(6382): p. 1350- 1355. 
23. Ronald, J.A., et al., A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft -
versus - Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res, 2017. 
77(11): p. 2893- 2902. doi: 10.1158/0008- 5472.CAN -16-2953  
24. Soler, C., Garcia -manteiga, J., Valdes, R., Xaus, J., Comalada, M., Casado, F.J., Pastor -
Anglada, M., Celada, A. and Felipe, A. (2001), Macrophages require different nucleoside transport systems for proliferation and activation. The FASEB Journal, 15: 1979- 1988. 
doi:10.1096/fj.01- 0022com  
25. Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbe, C., Hodi, F. S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune -related 
response criteria. Clin Cancer Res, 15(23), 7412- 7420. doi:10.1158/1078- 0432.ccr -09-1624  
  
 
 
 
   
 
 
 
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 42 of 43 
 APPENDICES  
Appendix 1: ECOG and Karnofsky Performance Status Scores1,2  
 
ECOG PERFORMANCE STATUS  KARNOFSKY PERFORMANCE STATUS  
0—Fully active, able to carry on all pre -disease 
performance without restriction  100—Normal, no complaints; no evidence of disease  
 90—Able to carry on normal activity; minor signs or 
symptoms of disease  
1—Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house 
work, office work   80—Normal activity with effort, some signs or 
symptoms of disease  
 70—Cares for self but unable to carry on normal 
activity or to do active work  
2—Ambulatory and capable of all selfcare but 
unable to carry out any work activities; up and about more than 50% of waking hours   60—Requires occasional assistance but is able to care 
for most of personal needs  
 50—Requires considerable assistance and frequent 
medical care  
3—Capable of only limited selfcare; confined to 
bed or chair more than 50% of waking hours   40—Disabled; requires special care and assistance  
 30—Severely disabled; hospitalization is indicated 
although death not imminent  
4—Completely disabled; cannot carry on any 
selfcare; totally confined to bed or chair   20—Very ill; hospitalization and active supportive 
care necessary  
 10—Moribund  
5—Dead    0—Dead  
1. Karnofsky D, Burchenal  J, The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed. 
Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191– 205. 
2. Zubrod C, et al. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and thiophosphoramide. Journal of Chronic Diseases; 1960:11:7- 33. 
 
  
  
[18F]F-ARAG /NSCLC   Clinical Study Protocol: CST -FARAG -203 
  Version 1.4: 04.23.202 4 
Department of Radiology   
Confidential   Page 43 of 43 Appendix 2: Study Registration and Participant visits  
A. The subject will sign and date the Informed Consent Form (ICF), and Health Insurance 
Portability and Accountability Act (HIPAA) authorization (according to site’s practices) prior 
to any study- related procedures with the exception of the standard- of-care ( SOC) 
diagnostic/tumor staging CT or MRI that would be accepted for imaging review to assess 
eligibility of NSCLC subjects, if done within 45 days prior to Visit 2.  
B. Once signed, informed consent has been obtained; patients will be entered on study.  To 
register a patient, the study coordinator must complete the Eligibility Checklist.  The study 
coordinator will register the patient onto the study and assign a unique a n Enrollment ID before 
initiation of the study drug administration.   
C. Pre-study laboratory tests must be completed prior to registration within the time frame 
specified in the protocol.   
D. A subject failing to meet all protocol requirements may not be registered.  If you have any 
questions regarding eligibility, please contact the coordinating site PI or Study Coordinator  
E. Unscheduled visits may be required in addition to the scheduled visits per the Investigator’s 
discretion. The details of these unscheduled visits with subjects will be recorded in the medical 
records and on the Case Report Form (CRF).  
F. If a subject misses a visit, the site is to make every effort to have the subject return as soon as possible to make up the visit. Once the subject is seen, he/she is to return to his/her original 
visit schedule. 
G. A subject who has signed the consent form but does not receive any [
18F]F-AraG infusion is 
classified as a screen failure. Subject number, demographic information, and reason for screen 
failure will be collected.  
H. A subject who is classified as a screen failure will be replaced. A subject who does not receive 
at least one infusion of [18F]F-AraG  and the associated PET/CT scans will also be replaced.  
 
 